MIIC 50/MIC90/% susceptible [CLSI] (no. tested)
| Antimicrobial | ESBL E. coli (471) | ESBL Klebsiella Spp. (661) | ESBL P. mirabilis (19) | CAZ-NS AmpC-ENTa (264) |
|---|---|---|---|---|
| Cefepime- tazobactam | 0.12/0.5/[96.2/98.7]b | 0.5/64/[65.5/73.7]b | 0.12/0.25/[100.0/100.0]b | 0.25/2/[92.8/96.2]b |
| Cefepime | 16/>64/23.4 | 32/>64/18.5 | 1/>64/57.9 | 0.5/16/74.6 |
| Piperacillin-tazobactam | 8/64/82.1 | >64/>64/36.8 | 1/8/100.0 | 32/>64/37.5 |
| Meropenem | <_0.06/ <_0.06/99.4 | <_0.06/>8/71.9 | <_0.06/ 0.12/100.0 | <_0.06/ 0.12/96.6 |
| levofloxacin | >4/>4/23.4 | 4/>8/41.1 | >4/>4/15.8 | 0.25/>4/77.7 |
| Gentamicin | 2/>8/51.8 | >8/>8/46.3 | 4/>8/57.9 | <_1/>8/79.2 |
- Pan-resistant organism as per culture report with evidence of invasive disease – fever/ leucocytosis/elevated procalcitonin (PCT) or culture from a sterile site.
- Clinical failure of all other classes of antibiotics over 72 hours
Cefepime-tazobactam is currently under clinical development at 2g/2g q8 hours as well as q12 hours dosage as a 90 minute infusion
INDICATIONS
- Empirical treatment for febrile neutropenia
- Moderate to severe pneumonia
- Complicated intra-abdominal infections
- Skin and skin structure infections